Vilanterol Trifenatate Drug Asset Due Diligence Report 2026

This Vilanterol Trifenatate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Discontinued

Highest phase

138

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Vilanterol Trifenatate can convert its Small molecule drug profile and β2-adrenergic receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Vilanterol Trifenatate (query alias: vilanterol)
Modality / target	Small molecule drug; β2-adrenergic receptor; β2-adrenergic receptor agonists
Highest global status	Discontinued
Originator	GSK Plc
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2025/12/098826	Phase 4	Not Yet Recruiting	234	Not disclosed
ChiCTR2600120078	Not Applicable	Completed	204	After 24 weeks, the change of trough FEV1 relative to baseline before administration.
NCT07541378	Not Applicable	Suspended	100	Endurance time during constant-work-rate cycle ergometry (CWRCE)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Assessment of Disease Stability in Patients With COPD Receiving Single-inhaler Therapy With Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI: Post Hoc Analysis of the IMPACT Trial

Phase 3; n=4151; evaluation: Positive. Reported fields: Disease stability = 17 % ; Disease stability = 26 % ; Disease stability = 19 %

Impact of Fluticasone Furoate/Umeclidinium/Vilanterol Inhaled Therapy on a Clinical Remission Endpoint in Asthma for Patients with Type 2 Inflammation: CAPTAIN Post Hoc Analysis

Phase 3; n=not disclosed; evaluation: not stated. Reported fields: CR endpoint at Week 24 = 24 % ; CR endpoint at Week 24 = 26 %

Clinical benefits with Fluticasone furoate/Umeclidinium/Vilanterol therapy for COPD: post hoc subgroup analysis of ELLITHE study

Not Applicable; n=617; evaluation: Positive. Reported fields: CAT(large responders) = 40.7 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Vilanterol Trifenatate addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2002-11-14	Theravance and GSK to codevelop LABAs for respiratory diseases worldwide	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Process to prepare vilanterol trifenatate”. The milestone feed surfaced a patent-application signal described as “Method for simultaneously detecting various gene impurities of vilanterol triphenylacetate”. The milestone feed surfaced a patent-application signal described as “Method for the purification of vilanterol trifenatate”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION